Article Text

PDF
Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test
  1. Bernard Denis1,
  2. Marcel Ruetsch2,
  3. Patrick Strentz2,
  4. Jean Yves Vogel2,
  5. Francis Guth2,
  6. Jean Marc Boyaval2,
  7. Xavier Pagnon2,
  8. Jean François Ebelin2,
  9. Isabelle Gendre2,
  10. Philippe Perrin2
  1. 1
    Médicine A–Hôpital Pasteur, Colmar, France
  2. 2
    ADECA68, 122 rue du Logelbach, Colmar, France
  1. Bernard Denis, Médecine A, Hôpital Pasteur, 39 avenue de la Liberté, 68024, Colmar, France; bernard.denis{at}ch-colmar.rss.fr

Abstract

Objective: To assess both feasibility and short term outcomes of a population based colorectal cancer screening programme using a biennial guaiac based faecal occult blood test (gFOBT).

Method: All participants were invited by mail to take part in a screening programme using a non-rehydrated gFOBT. The gFOBTs were first provided by general practitioners (GPs) and then directly mailed to individuals who failed to comply after two invitations. The setting was a French administrative district: Haut-Rhin (710 000 inhabitants). 182 981 residents aged 50–74 years were invited to participate.

Results: 19 274 people (10.5%) were excluded from gFOBT screening and 90 706 completed a gFOBT, so that the participation rate was 55.4% of those eligible. 76.5% of the completed gFOBTs were provided by GPs and 15.5% by direct mailing. The gFOBT positivity rate was 3.4%. The positive predictive value was 42.7% for neoplasia (women 30.8%, men 52.5%), 23.6% for advanced adenoma, and 7.6% for cancer. The number of normal colonoscopic procedures (without neoplasia) needed to be performed for each colonoscopy detecting an advanced neoplasia was 1.8, lower in men (1.2) than in women (3.4), and decreasing with age. Detection rates for neoplasia and cancer were 12.8 and 2.3 per 1000 people screened. 206 adenocarcinomas were detected: 47.6% were stage I and 23.8% stage II. The direct cost was estimated at €29.3 per screened person and €13 466 per cancer detected.

Conclusions: Participation and diagnostic yield of controlled trials of gFOBT screening are reproducible in the real world at an acceptable cost through an organised population based programme involving GPs.

  • colorectal neoplasms
  • screening
  • occult blood

Statistics from Altmetric.com

Footnotes

  • Funding: Financing was ensured through the French Sickness Fund (Assurance Maladie) and the Haut-Rhin Administration (Conseil Général du Haut-Rhin).

  • Conflict of interest: None.

  • Abbreviations:
    AJCC
    American Joint Committee on Cancer
    CRC
    colorectal cancer
    gFOBT
    guaiac based faecal occult blood test
    GP
    general practitioner
    TNM
    tumour-node-metastasis

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Digest
    Robin Spiller Emad M El-Omar